KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) EBITDA Margin (2016 - 2025)

Arbutus Biopharma's EBITDA Margin history spans 13 years, with the latest figure at 1452.55% for Q3 2025.

  • For Q3 2025, EBITDA Margin rose 368.0% year-over-year to 1452.55%; the TTM value through Sep 2025 reached 289.72%, up 83615.0%, while the annual FY2024 figure was 1128.41%, 73823.0% down from the prior year.
  • EBITDA Margin for Q3 2025 was 1452.55% at Arbutus Biopharma, down from 23.3% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 23.3% in Q2 2025 and bottomed at 1456.24% in Q3 2024.
  • The 5-year median for EBITDA Margin is 669.65% (2021), against an average of 685.27%.
  • The largest annual shift saw EBITDA Margin crashed -103717bps in 2024 before it soared 116658bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 669.65% in 2021, then soared by 49bps to 342.93% in 2022, then plummeted by -156bps to 878.74% in 2023, then increased by 9bps to 799.05% in 2024, then plummeted by -82bps to 1452.55% in 2025.
  • Per Business Quant, the three most recent readings for ABUS's EBITDA Margin are 1452.55% (Q3 2025), 23.3% (Q2 2025), and 1392.12% (Q1 2025).